Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in a filing to the US ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

The Spanish contract development and manufacturing organization (CDMO) Viralgen and UK gene therapy developer Axovia Therapeutics announced yesterday that they have joined forces to boost the ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few treatment options. Neogap is developing a personalized Tumor Trained Lymphocyte ...